Latest Headlines

  1. New Device Can Diagnose Covid-19 From Saliva Samples 8/6/2021

    Engineers at MIT and Harvard University have designed a small tabletop device that can detect SARS-CoV-2 from a saliva sample in about an hour. In a new study, they showed that the diagnostic is just as accurate as the PCR tests now used.

  2. Ortho Clinical Diagnostics Expands COVID-19 Test Offerings With Emergency Use Authorization (EUA) Of Total Nucleocapsid Antibody Test 8/5/2021

    Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its qualitative COVID-19 Total N antibody test received U.S. Food and Drug Administration EUA.

  3. Next Generation Automation Lab Achieves Huge Productivity Gains 8/5/2021

    Eli Lilly and Company and their industry partners, including sample management specialists – Ziath, are speeding the discovery of new medicines through the fully automated Lilly Life Sciences Studio (L2S2) lab in San Diego, USA.

  4. Immunovia, Inc. Receives Approval To Begin Testing Patients For Pancreatic Cancer With The IMMray™ PanCan-d Test 8/4/2021

    Immunovia AB (publ) ("Immunovia"), a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced that Immunovia, Inc. has received final approval to begin patient testing for the IMMray PanCan-d test - the first blood test on the market dedicated to the early detection of pancreatic cancer.

  5. Mel-Mont Medical Announces The Validation Of Its Patented Self-Sampling Technology, Mía By XytoTest®, For Molecular Screening Using HPV-DNA And 7-Type mRNA E6/E7 8/4/2021

    Mel-Mont Medical, a boutique medical device and technology company dedicated to improving women's health through the use of its DNA and mRNA patented self-sampling screening kit, Mia by XytoTest®, receives clinical validation as being equally effective to clinician-collected sampling.

  6. Empower Clinics Completes Landmark Kai Laboratory Expansion 8/4/2021

    Empower Clinics Inc. ("Empower" or the "Company") an integrated healthcare company - serving patients through medical centers, telemedicine platforms and a high complexity medical diagnostics laboratory processing thousands of COVID-19 specimens is delighted to announce the completion of its Kai Medical Laboratory ("Kai Lab") expansion.

  7. Accelerate Diagnostics Announces CE Mark And Availability In Europe Of Fast Antimicrobial Susceptibility Test For Use With Existing ID Systems 8/3/2021

    Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the new IVD configuration of its Accelerate PhenoTest® BC kit has been CE marked and is ready for use in Europe.

  8. Philips Genomics Workspace Enables Integration Of The Largest-Scale FDA-Cleared Cancer Genetic Test At NYU Langone Health 8/3/2021

    Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that New York Langone Health’s Department of Pathology will leverage Philips Genomics Workspace (formerly part of IntelliSpace Precision Medicine Platform) to integrate into their EMR (electronic medical record) environment.

  9. OpGen Achieves Key Development Milestone In Unyvero A30 RQ Platform Program 8/3/2021

    OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced that its subsidiary Curetis GmbH and its instrument development and engineering partner have assembled 10 final pre-series release analyzer instruments of the Unyvero A30 RQ platform.

  10. AXIM® Biotechnologies To Acquire Technology Including Two FDA-Cleared 510(k)’s For Diagnostic Testing Of Dry Eye Disease 8/3/2021

    AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a leader in the development of diagnostic testing for COVID-19 and cancer, announced today that the Company has signed a Binding Term Sheet to acquire the technology for the testing of Dry Eye Disease (DED), including two FDA authorizations and approvals for the commercial sale of two ophthalmic diagnostic lab tests.